Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Kaletra

Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 54–55

HOS-109014 · Präparat HOS-093083

54 Delamanid (100 mg Delamanid: Due to the risk of QTc prolongation BID) AUC: ↑ 22% associated with DM-6705, if co-administration of delamanid with (Lopinavir/ritonavir DM-6705 (delamanid active Kaletra is considered necessary, very 400/100 mg BID) metabolite): frequent ECG monitoring throughout AUC: ↑ 30% the full delamanid treatment period is recommended (see section 4.4 and A more pronounced effect on refer to the delamanid SmPC). DM-6705 exposure may be observed during prolonged co- administration with lopinavir/ritonavir. Rifabutin, 150 mg QD Rifabutin (parent drug and active When given with Kaletra the 25-O-desacetyl metabolite): recommended dose of rifabutin is AUC: ↑ 5.7-fold 150 mg 3 times per week on set days Cmax: ↑ 3.5-fold (for example Monday-Wednesday- Friday). Increased monitoring for rifabutin-associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to rifabutin. Further dosage reduction of rifabutin to 150 mg twice weekly on set days is recommended for patients in whom the 150 mg dose 3 times per week is not tolerated. It should be kept in mind that the twice weekly dosage of 150 mg may not provide an optimal exposure to rifabutin thus leading to a risk of rifamycin resistance and a treatment failure. No dose adjustment is needed for Kaletra.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)